|
EMEA Recommends Additional Studies for High-Risk Drugs
Sponsors wishing to test high-risk new drugs for the first time on human subjects are advised to undertake additional preliminary studies in some circumstances under a new draft guideline from the European Medicines Agency (EMEA). This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives